Production, quality control and pharmacokinetic studies of 166Ho-EDTMP for therapeutic applications

17Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

166Ho-EDTMP is a major therapeutic agent which is widely used in bone palliation therapy. In this study, a 166Ho-EDTMP complex was prepared successfully using an in-house synthesized EDTMP ligand and 166HoCl3. Ho-166 chloride was obtained by thermal neutron irradiation (1 × 1013 ncm-2s-1) of natural Ho(NO3)3 samples (specific activity = 3-5 GBq/mg), dissolved in acidic media. The radiochemical purity of 166Ho-EDTMP was checked by ITLC (>99%) and stability studies in presence of human serum and final preparation were performed. The biodistribution of 166Ho-EDTMP and 166HoCl3 in wild-type rats was checked by scarification. SPECT imaging of 166Ho-EDTMP was also performed in wild-type rats. A comparative accumulation study for 166Ho-EDTMP and 166HoCl3 was performed for vital organs up to 48h. Significant bone accumulation (>70%) of the tracer in 48h was observed. © Bahrami-Samani et al.

Cite

CITATION STYLE

APA

Bahrami-Samani, A., Bagheri, R., Jalilian, A. R., Shirvani-Arani, S., Ghannadi-Maragheh, M., & Shamsaee, M. (2010). Production, quality control and pharmacokinetic studies of 166Ho-EDTMP for therapeutic applications. Scientia Pharmaceutica, 78(3), 423–433. https://doi.org/10.3797/scipharm.1004-21

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free